Cytokinetics, Incorporated Revenue 2009–2025
Cytokinetics, Incorporated annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Cytokinetics, Incorporated revenue for the quarter ending March 31, 2026 was 19.4 M, a 1125.78% increase year-over-year.
- Cytokinetics, Incorporated revenue for the twelve months ending March 31, 2026 was 89.6 M, a 4556.57% increase year-over-year.
- Cytokinetics, Incorporated annual revenue for 2025 was 88.0 M, a 376.56% increase from 2024.
- Cytokinetics, Incorporated annual revenue for 2024 was 18.5 M, a 145.34% increase from 2023.
- Cytokinetics, Incorporated annual revenue for 2023 was 7.5 M, a 92.04% decrease from 2022.
- Cytokinetics, Incorporated annual revenue for 2022 was 94.6 M.
Cytokinetics, Incorporated (CYTK) — Frequently Asked Questions
Cytokinetics, Incorporated (CYTK) is a publicly traded US company. It has a market capitalization of $8M. In fiscal 2025 it reported revenue of $88M and net income of -$785M. Explore CYTK's stock price, financial statements, earnings history, margins and key ratios below.
What is Cytokinetics, Incorporated's market cap?
Cytokinetics, Incorporated (CYTK) has a market capitalization of $8M.
What is the CYTK stock price?
CYTK trades at $69.21 (+3.19% on the day).
How much revenue does Cytokinetics, Incorporated make?
Cytokinetics, Incorporated reported revenue of $88M in fiscal 2025.
Is CYTK profitable?
In fiscal 2025, Cytokinetics, Incorporated reported net income of -$785M.